

Received: 21 September 2015 Revised: 14 May 2016 Accepted: 20 May 2016

DOI: 10.1111/cep.1

ORIGINAL ARTICLE

Effects of transthyretin on thyroxine and β -amyloid removal from cerebrospinal fluid in mice

Ruoli Chen^{1,2} Carl P Chen^{1,3} Jane E Preston¹

¹Institute of Pharmaceutical Science, King's College London, London, SE1 7UL UK

²Institute of Science and Technology of Medicine, School of Pharmacy, Keele University, Staffordshire ST5 5BG, UK

³Department of Physical Medicine and Rehabilitation, Chang Gung Memorial Hospital at Linkou, College of Medicine, Chang Gung University, Kwei Shan, Taoyuan County, Taiwan, China

Correspondence

Dr Ruoli Chen

Institution of Science and Technology of Medicine, School of Pharmacy, Keele University, Staffordshire ST5 5BG, UK

Email: r.chen@keele.ac.uk

Summary

Transthyretin (TTR) is a binding protein for the thyroid hormone thyroxine (T_4), retinol and β -amyloid peptide. TTR aids the transfer of T_4 from the blood to the cerebrospinal fluid (CSF), but also prevents T_4 loss from the blood-CSF barrier. It is, however, unclear whether TTR affects the clearance of β -amyloid from the CSF. This study aimed to investigate roles of TTR in β -amyloid and T_4 efflux from the CSF. Eight-week-old 129sv male mice were anaesthetized and their lateral ventricles were cannulated. Mice were infused with artificial CSF containing ^{125}I - T_4 / ^3H -mannitol, or ^{125}I -A β 40 / ^3H -inulin, in the presence or absence of TTR. Mice were decapitated at 2, 4, 8, 16, 24 minutes after injection. The whole brain was then removed and divided into different regions. The radioactivities in the brain were determined by liquid

scintillation counting. At baseline, the net uptake of $^{125}\text{I-T}_4$ into the brain was significantly higher than that of $^{125}\text{I-A}\beta_4$, and the half time for efflux was shorter ($^{125}\text{I-T}_4$, 5.16; $^3\text{H-mannitol}$, 7.44; $^{125}\text{I-A}\beta_4$, 8.34; $^3\text{H-inulin}$, 10.78 minutes). The presence of TTR increased the half time for efflux of $^{125}\text{I-T}_4$ efflux, and caused a noticeable increase in the uptake of $^{125}\text{I-T}_4$ and $^{125}\text{I-A}\beta_4$ in the choroid plexus, whilst uptakes of $^3\text{H-mannitol}$ and $^3\text{H-inulin}$ remained similar to control experiments. This study indicates that thyroxine and amyloid peptide effuse from the CSF using different transporters. TTR binds to thyroxine and amyloid peptide to prevent the loss of thyroxine from the brain and redistribute amyloid peptide to the choroid plexus.

KEYWORDS

Alzheimer's Disease, β -amyloid, choroid plexus, CSF, efflux TTR, thyroxine

1 INTRODUCTION

Transthyretin (TTR), a highly conserved tetrameric protein of 55 kDa, is synthesized mainly in the liver and is also present in the choroid plexus (CP) and retina and in the cytoplasm of ependymal cells of brain ventricles.¹ The CP contains 10 times more TTR mRNA in per gram of tissue than liver and secretes TTR at rate 13 times greater than liver.² TTR production accounts for at least 20% of all protein synthesised by the CPs in the rat, and contributes approximately 50% of all secreted proteins into the cerebrospinal fluid (CSF).^{3,4} About 6% of total protein in CSF is TTR (~15 $\mu\text{g TTR mL}^{-1}$ of CSF), which binds 80% of T_4 in the CSF.⁵

The secretion of TTR by the CP into CSF has been suggested to play a key role in the transfer of T_4 from the blood to the CSF, as a unidirectional secretion of TTR to the CSF may drive thyroxine hormones (TH) across the blood-CSF barrier (BCB).⁶ In humans, TTR transports about 15% of plasma T_4 , and the rest of T_4 are carried with other TH distributing proteins, e.g. thyroxine binding proteins (TBG), albumin.⁷ In TTR knockout (KO) mice, TTR absence does not impair TH tissue contents, despite the low circulating levels of total T_4 .^{8,9} These observations are in agreement with the free hormone hypothesis, that the hormone biological activity depends only on its free plasma concentration.¹⁰ In the CSF, TTR is a major T_4 carrier.⁵ It was reported that T_4 distribution from the CSF into the brain is TTR-

dependent and occurs via receptor-mediated endocytosis.^{11,12} The TTR-T₄ interaction poses a preferential relevance in the brain than in the peripheral circulation, given there are two other T₄ transporter proteins besides TTR being present in plasma with TBG having the highest affinity for T₄, whereas TTR is the major carrier for T₄ in the CSF.

Besides being the carrier of T₄ and retinol, TTR has been suggested to bind β -amyloid peptide (A β) essentially protecting the brain from neurotoxic accumulations called amyloid plaques, a hallmark of Alzheimer's disease (AD).¹³⁻¹⁶ TTR binds to both A β monomers and oligomers, but preferentially binds to the latter.¹⁷ TTR suppressed A β aggregation *in vitro* via an interaction between the thyroxine binding pocket of the TTR and A β residues 18-21,¹⁴ and prevents its toxicity.¹⁸ In rat CP epithelial cell culture experiments, TTR was found to sequester A β in the CSF and guided A β to the CP for enzymatic degradation and removal.^{19, 20} TTR is suggested as a protease with apolipoprotein A-I (apoA-I) and A β as substrates.²¹ TTR cleaves A β in multiple positions with some of the generated A β peptides displaying lower amyloidogenic potential than the full-length counterpart.¹⁸ As TTR was able to degrade aggregated forms of A β , it may contribute not only to the maintenance of A β levels within a normal range, but also to the removal of deposited A β in case of imbalance and disease.

TTR-A β interaction seems to have a neuroprotective effect in AD patients. TTR levels in the brains of AD patients are negatively correlated with the abundance of amyloid plaques,²² and TTR is upregulated in response to elevated A β levels in transgenic mice overexpressing mutant amyloid precursor protein.²³ Significant reduction of TTR concentration in CSF of AD patients, compared to normal age controls was found by a number of studies,²⁴⁻²⁷ suggesting the AD patients either having reduced TTR production or depleting TTR with enhanced level of A β in the brain. While Schultz *et al.*²⁸ did not find significant changes in TTR in CSF between AD patients and normal controls, but found a significant reduction in CSF TTR (14%) in AD patients who were medicated with cholinesterase inhibitors compared to those AD patients who were not.

This study was to characterize roles of TTR on β -amyloid clearance from CSF in comparison to thyroxine (T_4) using an *in situ* mouse brain perfusion technique, and unravel mechanism of both T_4 and $A\beta$ efflux in a physiology model.

2. RESULTS

2.1. Baseline distribution of $^{125}\text{I-T}_4$ / $^{125}\text{I-A}\beta 40$ in the brain

At baseline, levels of both $^{125}\text{I-T}_4$ and $^{125}\text{I-A}\beta 40$ in the brain were significantly higher than their size matched extracellular markers (mannitol and inulin), suggesting active uptakes of T_4 and $A\beta 40$ (Fig 1a, Fig 2a). Regionally, net levels of $^{125}\text{I-T}_4$ and $^{125}\text{I-A}\beta 40$ in the CP, EP, were higher than those in FX and CB, presumably the latter tissues were further away from the injection site – the lateral ventricles (Figs. 3,4).

2.2. Efflux half time of $^{125}\text{I-T}_4$ / $^{125}\text{I-A}\beta 40$

Levels of $^{125}\text{I-T}_4$, $^{125}\text{I-A}\beta 40$ as well as the extracellular markers fell over time in whole brain and in the CSF secreting CP (Figs. 1,2). These generated linear relation curves, by which the half time for efflux was calculated as in the Table 1. Table 1 showed the efflux half time of both $^{125}\text{I-T}_4$ and $^{125}\text{I-A}\beta 40$ were shorter than their size matched extracellular markers (mannitol and inulin), suggesting specific transporters for $^{125}\text{I-T}_4$ and $^{125}\text{I-A}\beta 40$.

2.3. Effects of TTR on $^{125}\text{I-T}_4$ / $^{125}\text{I-A}\beta 40$ in the brain

In the presence of TTR, levels of $^{125}\text{I-T}_4$ fell over the time but at slower rates, leading to significant prolonged half time of $^{125}\text{I-T}_4$ efflux in brain parenchyma (Fig. 1, Table 1). However, TTR did not significantly change the $^{125}\text{I-A}\beta 40$ efflux half time in brain parenchyma (Fig. 2, Table 1). There was a noticeable increase in the uptake of $^{125}\text{I-T}_4$ and $^{125}\text{I-A}\beta 40$ in the CP in presence of TTR compared to the baseline, whilst uptakes of ^3H -mannitol and ^3H -inulin remained similar to control experiments (Fig. 3,4). TTR had no significant effect on the integrities of $^{125}\text{I-A}\beta 40$, as the percentage of loss of ^{125}I activity (cpm in supernatant) were almost equal in treatment groups ($41.3 \pm 4.5\%$ and $42.7 \pm 5\%$ in TTR 50, 200 $\mu\text{g/mL}$ respectively, versus $41.5 \pm 6.3\%$ in control group, $P > 0.05$).

3. DISCUSSION

This study investigated the effect of TTR on T₄ and amyloid efflux from the CSF. At baseline (without TTR), both ¹²⁵I-T₄ (775 Da) and ¹²⁵I-Aβ40 (4455 Da) were cleared from brain faster than their corresponding extracellular markers, ³H-mannitol (182 Da) and ³H-inulin (5000 Da), consistent with the concept of specific transporters for ¹²⁵I-T₄ and ¹²⁵I-Aβ40, in addition to the diffusion and fluid drainage pathways accessible by mannitol and inulin. With TTR in aCSF, the loss of thyroxine from the brain was significantly reduced (i.e. efflux half time was prolonged), while the retention of Aβ40 in the brain was not significantly affected (i.e. efflux half time was not changed). In presence of TTR, the accumulation of both ¹²⁵I-T₄ and ¹²⁵I-Aβ40 in the CP were significantly increased. Since the nascent CSF is washed out from the ventricular system during perfusion with artificial CSF in the experiments, the CSF endogenous TTR approaches zero in these mice during the perfusion.

TTR is a protein that binds and distributes the TH in the body. In the blood, >99% of TH is bound to specific plasma proteins known as TH distributor proteins, such as TBG, TTR, albumin and ApoB100.⁷ These TH binding proteins maintain the large extrathyroidal pool of TH which can be liberated with great rapidity for entry into cells, ensure a constant supply of TH to the cells and tissues.^{1, 7} In the CSF, TTR assumes the main role in terms of TH homeostasis, as TTR has higher affinity to T₄ than the albumin (~5–9 × 10⁻⁸ mol/L vs ~7 × 10⁻⁵M).¹ We showed here that TTR affected T₄ distribution in the brain and prevented the T₄ loss from the brain. The increased accumulation of T₄ in the CP by TTR may be due to reduced basolateral efflux (from choroid epithelial cells to plasma) as well as an augmented uptake of T₄ from CSF. The T₄ efflux from the CSF involves a number of transporters²⁹ and is saturable in presence of unlabelled T₄.^{9, 11, 30} Despite the important role of TTR in TH homeostasis, mice lacking the TTR gene maintain normal functioning of thyroid glands in the face of significant reduction in total serum T₄ concentration.⁹ Using the same model it was found that TTR was not essential for TH to reach the brain.⁸ This is not surprising given there are numerous mechanisms for T₄ transport, and a number of thyroxine binding proteins may take over the role of TTR in TTR-null mice. Despite the apparent normal distribution of T₄ in the brain, TTR knock-out mice have behavioural changes, which

are associated with an apparent increase of noradrenaline in the limbic forebrain of the mice.^{31, 32}

It has been suggested that TTR has other important physiological effects. TTR could bind A β and prevent amyloid formation, and also inhibit A β induced cytotoxicity.^{13, 14, 18} A β deposition in the brain has been linked to the AD pathogenesis. The accumulation of A β in the AD brain is suggested to be related to defective A β clearance from the brain rather than increased A β production.³³ P-gp and low-density lipoprotein receptor-related protein-1 (LRP-1) in cerebrovasculature have been reported to play important roles in A β clearance from the brain to the blood.³⁴ A recent study demonstrated that TTR interacted with A β directly and stimulated brain-to-blood but not blood-to-brain A β permeability in hCMEC/D3, a human cerebral microvascular endothelial cell line.³⁵ Together with one of their previous studies,³⁶ they conclude that TTR acts as an A β carrier that transports the peptide to its receptor both at blood brain barriers in the brain and at the liver in the peripheral system.^{35, 36} In the current study, we intended to use TTR concentrations close to the physiology level in mouse CSF (20–50 $\mu\text{g/mL}$),³⁷ which are more than that of ¹²⁵I – A β 40. The TTR dose effect was not seen. Thus, we could use one dose of TTR (i.e. 50 $\mu\text{g/mL}$) in the study. That will be close to the clinical setting. At physiological condition in human, TTR is abundant (5–20 $\mu\text{g/mL}$ or 0.1–0.36 $\mu\text{mol/L}$)³⁸ while A β concentration in CSF is relatively low (3 nmol/L or less).^{39, 40} The effects of TTR on A β neurotoxicity have also been demonstrated in *in vivo* experiments. The silencing the endogenous TTR gene accelerated the appearance of A β associated neuropathology, while genetically programmed overexpression of a human TTR transgene suppressed both the neuropathologic and behavioural abnormalities in the APP23 transgenic mouse model.⁴¹ Backcrossing of the TTR null mice with an AD mouse model resulted in an increase in the deposition of A β in the brains of mice with the hemizygous deletion of TTR.⁴² TTR concentration in the CSF was found to negatively correlate with AD patients,⁴³ as well as the degree of dementia in patients with AD.⁴⁴ However, TTR was not found to change in AD patients compared to age-matched controls in a number of larger AD clinical studies such as ADNI (The Alzheimer's disease neuroimaging initiative).^{28, 45}

As the main tissue in the brain to secrete CSF and synthesize TTR, the CP is suggested to be a major site of A β removal in the brain. In a triple transgenic mouse model of AD, CP dysfunction was shown linking to increasing A β burden resulting in reduced production of CSF and diminished secretion of TTR.⁴⁶ In AD patients, CSF

turnover/clearance is decreased by 50%.⁴⁷ It will decrease A β 40 clearance from the brain and increase the contact time for proteins with glucose in the CSF, which promotes the glycosylation of CSF proteins and increased oxidative stress.⁴⁸ The CP also contains high levels of A β degrading enzymes, such as neprilysin, endothelin-converting enzyme-1, insulin degrading enzyme,¹⁹ which degrade β -amyloid peptides. In our study we showed TTR bound to A β 40 and distributed A β 40 to the CP, as the CP has high affinity to TTR due to presence of TTR receptor.⁴⁹ We found significant loss of the integrity of ¹²⁵I-A β / TTR complex in the brain tissue detected by the TCA precipitation assay. The loss of radioisotope activity in the precipitate could be due to involvement of enzymatic degradation in the CP, blood brain barrier or brain parenchyma. The accumulation / degradation of A β 40 in the CP enhance A β 40 removal which is known to occur at the CPs via receptor mediated processes (e.g. via the LRP1) that are modulated by chaperone complexes such as ApoE, clusterin, TTR.⁵⁰ In the CP, the abundance of LRP-1 increases with age, whereas the abundance of LRP-2 (megalin) is reduced during normal ageing in rodents.⁵¹ Megalin is thought to contribute to the clearance of A β through the CP,⁵² and patients with AD have reduced levels of megalin at the CP.⁵³ Since the BBB is not intact with the clearance deficits in the AD patients, the role of A β transport and degradation at the CP becomes increasingly more prominent and needs further investigating.

In conclusion, this study demonstrates that TTR acts differentially on T₄ and A β 40 efflux from the CSF. TTR prevents the loss of thyroxine from the CSF, a positive adaptation since T₄ is a substrate for multiple efflux transporters from the CSF, but is a necessary requirement for normal brain function. TTR does not significantly affect the retention of A β 40 in the brain parenchyma, but redistributes A β 40 to the CP for degradation and clearance. As a major site of TTR synthesis in the brain, the CP is an important site for homeostasis of TTR binding hormone and peptides.

4. METHODS

4.1. Mouse lateral ventricular perfusion

All procedures were within the guidelines of the Animals (Scientific procedures) Act, UK, 1986. Eight-week-old C57/BL6 male mice (20–25 g) were ordered from Harlan (Huntington, UK) and were kept on a 12-hour light/dark cycle with food and water

freely available. They were anaesthetized with i.p. 0.1 mL Vetalar (100 mg/mL ketamine anaesthetic) and 0.2 mL Domitor (1 mg/mL medetomidine analgesic/sedative) and injected with heparin (1000 U/kg). The mice were put on a stereotaxic frame, the scalp removed and a hole made in the skull above each lateral ventricle, 1.0 mm lateral and 1.0 mm posterior to the bregma. A 33 gauge needle was used to make the hole, and had a tubing guard which kept the depth of the holes constant (2.5 mm).

A syringe driver contained artificial CSF (aCSF) (all g/L: NaCl, 6.821; KCl, 0.2238; MgCl₂ 6H₂O, 0.1626; Na₂HPO₄, 0.0994; NaHCO₃, 1.512; Urea, 0.1202; Glucose, 2.178; CaCl₂4H₂O, 0.2058) with either ¹²⁵I-T₄ (0.037 MBq/mL; 8.62 nmol/L) plus ³H-mannitol (0.148 MBq/mL; 26.47 μmol/L) or ¹²⁵I-Aβ40 (0.09 MBq/mL; 1.1 nmol/L) plus ³H inulin (0.37 MBq/mL; 15.4 μmol/L) was run at 1 μL.min⁻¹ for 1 min at either absence or presence of TTR (50 or 200 μg/mL). Aβ40 was studied in this study, as it is several folds higher than Aβ42 in the brain and its accumulation disrupts the integrity of BBB,⁵⁴ although Aβ40 is less pathogenic than Aβ42 due to its low propensity to aggregate.⁵⁵ The radio-labelled mannitol (182 Da) and inulin (5000 Da) acted as size-matched, non-transported, extracellular markers for ¹²⁵I-T₄ (775 Da) and ¹²⁵I-Aβ40 (4455 Da) respectively. Radio-isotopes were purchased from GE Life Sciences (Little Chalfont, England) and Perkin-Elmer (Boston, MA, USA).

Human TTR (huTTR) was obtained from Biodesign International (Saco, ME, USA) and dissolved in saline. 100 μL of either ¹²⁵I-T₄ (0.037 MBq/mL; 8.62 nmol/L) or ¹²⁵I-Aβ40 (0.09 MBq/mL; 1.1 nmol/L) was mixed with 1 mL of TTR (50/200 μg/mL; 0.909/3.636 μmol/L). The mixture was allowed to bind for 30 minutes at room temperature and was then dialyzed overnight at 4 °C in seamless cellulose tubing (with a cutoff of 12 kD mol wet) (Sigma, St. Louis, MO, USA) to remove any unbound T₄ or Aβ40.

4.2. Sampling of the brain tissue, TCA precipitation and radioactive counting

At 2, 4, 8, 16, 24 minutes after the injection, the mice were killed with an overdose sodium pentobarbital. The heart was exposed and blood taken using a syringe inserted in the left ventricle. The brain was then washed with cold phosphate buffered saline

(PBS) and was dissected into right and left frontal cortex (FX), choroid plexus (CP), ependymal lining lateral ventricles (EP), hippocampus (HC), cerebellum (CB) and rest of brain (ROB). Samples were weighed on a Cahn microbalance (ThermoScientific, Waltham, MA, USA), and homogenized with PBS in a glass homogenizer.

The TCA precipitation method was used to determine how much ^{125}I was still attached to $\text{A}\beta$ at the end of the experiments.⁵⁶ To measure intact $^{125}\text{I}\text{-A}\beta$, one volume of TCA (20%) was added to the sample, and then samples were vortexed, incubated in ice for 30 minutes and centrifuged at 14,000 rpm at 4 °C for 30 minutes. Following centrifugation, radioactivity of precipitated $^{125}\text{I}\text{-A}\beta_{40}$ (intact peptide) and TCA supernatant (degraded peptide) were measured on a LKB Rackbeta liquid scintillation counter (Wallac, Turku, Finland). Solvables (National Diagnostics, Yorkshire, UK) was added to each of samples to dissolve organic samples overnight. The radioactivities of the tissues and 100 μL of infused aCSF were determined by liquid scintillation counting (LKB Wallac Rackbeta Spectral 1219 counter) after the addition of 3.0 mL liquid scintillation fluid (Ultima Gold, Packard Bioscience, Groningen, the Netherlands).

4.3. Expression of results

Regional brain uptake (volume of distribution) was calculated using the equation:

$$\text{Vd (mL/g)} = 100 \times (\text{Tissue dpm/g}) / (\text{aCSF dpm/mL}) \quad (1)$$

The half-time for efflux of $^{125}\text{I}\text{-T}_4$ and $^{125}\text{I}\text{-A}\beta_{40}$ from brain was calculated according to Banks et al [57]. Briefly, LogVd was plotted against time and the slope of the line was calculated where:

$$\text{Efflux half time (minutes)} = \text{Log}2 / \text{slope of line} \quad (2)$$

4.4. Data analysis

All values are expressed as mean \pm standard error of the mean (SEM). ANOVA and unpaired t-test as appropriate were used to compare means. Values of $P < 0.05$ were considered statistically significant.

ACKNOWLEDGMENTS

We are grateful for funding received from the Biotechnological and Biological Research Council, UK (BBD01381X1).

REFERENCES

1. Alshehri B, D'Souza DG, Lee JY, Petratos S, Richardson SJ. The diversity of mechanisms influenced by transthyretin in neurobiology: development, disease and endocrine disruption. *J. Neuroendocrinol.* 2015; 27: 303–23.
2. Dickson PW, Schreiber G. High levels of messenger RNA for transthyretin (prealbumin) in human choroid plexus. *Neurosci. Lett.* 1986; 66: 311–5.
3. Dickson PW, Aldred AR, Marley PD, Bannister D, Schreiber G. Rat choroid plexus specializes in the synthesis and the secretion of transthyretin (prealbumin). Regulation of transthyretin synthesis in choroid plexus is independent from that in liver. *J. Biol. Chem.* 1986; 261: 3475–8.
4. Fung WP, Thomas T, Dickson PW *et al.* Structure and expression of the rat transthyretin (prealbumin) gene. *J. Biol. Chem.* 1988; 263: 480–8.
5. Hu S, Loo JA, Wong DT. Human body fluid proteome analysis. *Proteomics* 2006; 6: 6326–53.
6. Southwell BR, Duan W, Alcorn D *et al.* Thyroxine transport to the brain: role of protein synthesis by the choroid plexus. *Endocrinol.* 1993; 133: 2116–26.
7. Richardson SJ, Wijayagunaratne RC, D'Souza DG, Darras VM, van Herck SLJ. Transport of thyroid hormones via the choroid plexus into the brain: the roles of transthyretin and thyroid hormone transmembrane transporters. *Frontiers. Neurosci.* 2005; 9: 1–8.

8. Sousa JC, de Escobar GM, Oliveira P, Saraiva MJ, Palha JA. Transthyretin is not necessary for thyroid hormone metabolism in conditions of increased hormone demand. *J. Endocrinol.* 2005; 187: 257–66.
9. Palha JA, Hays MT, Morreale de Escobar G, Episkopou V, Gottesman ME, Saraiva MJ. Transthyretin is not essential for thyroxine to reach the brain and other tissues in transthyretin-null mice. *Am. J. Physiol.* 1997; 272: E485–93.
10. Mendel CM. The free hormone hypothesis: a physiologically based mathematical model. *Endocr. Rev.* 1989; 10: 232–74.
11. Kassem NA, Deane R, Segal MR, Preston JE. Role of transthyretin in thyroxine transfer from cerebrospinal fluid to brain and choroid plexus. *Am. J. Physiol. Regul. Integr. Comp. Physiol.* 2006; 291: R1310–5.
12. Chen RL, Kassem NA, Preston JE. Dose-dependent transthyretin inhibition of T₄ uptake from cerebrospinal fluid in sheep. *Neurosci. Lett.* 2006; 396: 7–11.
13. Schwarzman AL, Gregori L, Vitek MP *et al.* Transthyretin sequesters amyloid beta protein and prevents amyloid formation. *Proc. Natl. Acad. Sci. USA.* 1994; 91: 8368–72.
14. Li X, Zhang X, Ladiwala AR *et al.* Mechanisms of transthyretin inhibition of β -amyloid aggregation *in vitro*. *J Neurosci.* 2013; 33: 19423–33.
15. Yang DT, Joshi G, Cho PY, Johnson JA, Murphy RM. Transthyretin as both a sensor and a scavenger of β -amyloid oligomers. *Biochemistry* 2013; 52: 2849–61.
16. Cho PY, Joshi G, Boersma MD, Johnson JA, Murphy RM. A cyclic peptide mimic of the β -amyloid binding domain on transthyretin. *ACS Chem Neurosci.* 2015; 6: 778–89.
17. Du J, Murphy RM. Characterization of the interaction of β -amyloid with transthyretin monomers and tetramers. *Biochemistry* 2010; 49: 8276–89.

18. Costa R, Ferreira-da-Silva F, Saraiva MJ, Cardoso I. Transthyretin protects against A-beta peptide toxicity by proteolytic cleavage of the peptide: a mechanism sensitive to the Kunitz protease inhibitor. *PLoS One* 2008; 3: e2899.
19. Crossgrove JS, Li GT, Zheng W. The choroid plexus removes beta- amyloid from brain cerebrospinal fluid. *Exp. Biol. Med. (Maywood)* 2005; 230: 771– 6.
20. Crossgrove JS, Smith EL, Zheng W. Macromolecules involved in production and metabolism of beta-amyloid at the brain barriers. *Brain. Res.* 2007; 1138: 187–95.
21. Liz MA, Mar FM, Franquinho F, Sousa MM. Aboard transthyretin: from transport to cleavage. *IUBMB Life* 2010; 62: 429–35.
22. Merched A, Serot JM, Visvikis S, Aguilon D, Faure G, Siest G. Apolipoprotein E, transthyretin and actin in the CSF of Alzheimer's patients: relation with the senile plaques and cytoskeleton biochemistry. *FEBS Lett.* 1998; 425: 225–8.
23. Stein TD, Johnson JA. Lack of neurodegeneration in transgenic mice overexpressing mutant amyloid precursor protein is associated with increased levels of transthyretin and the activation of cell survival pathways. *J. Neurosci.* 2002; 22: 7380–8.
24. Serot JM, Christmann D, Dubost T, Couturier M. Cerebrospinal fluid transthyretin: aging and late onset Alzheimer's disease. *J. Neurol. Neurosurg. Psychiatry* 1997; 63: 506–8.
25. Castaño EM, Roher AE, Esh CL, Kokjohn TA, Beach T. Comparative proteomics of cerebrospinal fluid in neuropathologically – confirmed Alzheimer's disease and non-demented elderly subjects. *Neurol. Res.* 2006; 28:155–63.
26. Gloeckner SF, Meyne F, Wagner F *et al.* Quantitative analysis of transthyretin, tau and amyloid-beta in patients with dementia. *J. Alzheimers Dis.* 2008; 14: 17–25.
27. Hansson SF, Andréasson U, Wall M *et al.* Reduced levels of amyloid-beta-binding proteins in cerebrospinal fluid from Alzheimer's disease patients. *J. Alzheimers Dis.* 2009; 16: 389–97.

28. Schultz K, Nilsson K, Nielsen JE *et al.* Transthyretin as a potential CSF biomarker for Alzheimer's disease and dementia with Lewy bodies: effects of treatment with cholinesterase inhibitors. *Eur. J. Neurol.* 2010; 17: 456–60.
29. Zibara K, El-Zein A, Joumaa W, El-Sayyad M, Mondello S, Kassem N. Thyroxine transfer from cerebrospinal fluid into choroid plexus and brain is affected by brefeldin A, low sodium, BCH, and phloretin, in ventriculo-cisternal perfused rabbits. *Front Cell Dev Biol.* 2015; 3: 60.
30. Zheng W, Deane R, Redzic Z, Preston JE, Segal MB. Transport of [L-125I]thyroxine by in situ perfused ovine choroid plexus: inhibition by lead exposure. *J Toxicol Environ Health A.* 2003; 66 :435–51.
31. Sousa JC, Grandela C, Fernández-Ruiz J *et al.* Transthyretin is involved in depression-like behaviour and exploratory activity. *J. Neurochem.* 2004; 88: 1052–8.
32. Buxbaum JN, Roberts AJ, Adame A, Masliah E. Silencing of murine transthyretin and retinol binding protein genes has distinct and shared behavioral and neuropathologic effects. *Neuroscience.* 2014; 275: 352–64.
33. Deane R, Bell RD, Sagare A, Zlokovic BV. Clearance of amyloid-beta peptide across the blood-brain barrier: implication for therapies in Alzheimer's disease. *CNS. Neurol. Disord. Drug. Targets.* 2009; 8: 16–30.
34. Qosa H, Abuznait AH, Hill RA, Kaddoumi A. Enhanced brain amyloid- β clearance by rifampicin and caffeine as a possible protective mechanism against Alzheimer's disease. *J Alzheimers Dis.* 2012; 31: 151–65.
35. Alemi M, Gaiteiro C, Ribeiro CA *et al.* Transthyretin participates in beta-amyloid transport from the brain to the liver- involvement of the low-density lipoprotein receptor-related protein 1? *Sci Rep.* 2016; 6: 20164.
36. Ribeiro CA, Oliveira SM, Guido LF *et al.* Transthyretin stabilization by iododiflunisal promotes amyloid- β peptide clearance, decreases its deposition, and ameliorates cognitive deficits in an Alzheimer's disease mouse model. *J Alzheimers Dis.* 2014; 39: 357–70.

37. Quintela T, Alves CH, Gonçalves I, Baltazar G, Saraiva MJ, Santos CR. 5 α -dihydrotestosterone up-regulates transthyretin levels in mice and rat choroid plexus via an androgen receptor independent pathway. *Brain Res.* 2008; 1229: 18–26.
38. Vatassery GT, Quach HT, Smith WE, Benson BA, Eckfeldt JH. A sensitive assay of transthyretin (prealbumin) in human cerebrospinal fluid in nanogram amounts by ELISA. *Clin Chim Acta.* 1991; 197: 19–25.
39. Price JM, Chi X, Hellermann G, Sutton ET. Physiological levels of beta-amyloid induce cerebral vessel dysfunction and reduce endothelial nitric oxide production. *Neurol Res.* 2001; 23: 506–12.
40. Hulstaert F, Blennow K, Ivanoiu A *et al.* Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF. *Neurology.* 1999; 52: 1555–62.
41. Li X, Masliah E, Reixach N, Buxbaum JN. Neuronal production of transthyretin in human and murine Alzheimer's disease: is it protective? *J. Neurosci.* 2011; 31: 12483–90.
42. Choi SH, Leight SN, Lee VM *et al.* Accelerated A β deposition in APP^{swe} / PS1 Δ E9 mice with hemizygous deletions of TTR (transthyretin). *J. Neurosci.* 2007; 27: 7006–10.
43. Elovaara I, Maury C, Palo J. Serum amyloid A protein, albumin and prealbumin in Alzheimer's disease and in demented patients with Down's syndrome. *Acta Neurol. Scand.* 1986; 74: 245–50.
44. Riisøen H. Reduced prealbumin (transthyretin) in CSF of severely demented patients with Alzheimer's disease. *Acta. Neurol. Scand.* 1988; 78: 455–9.
45. Weiner MW, Veitch DP, Aisen PS *et al.* Alzheimer's Disease neuroimaging initiative. 2014 Update of the Alzheimer's Disease neuroimaging initiative: a review of papers published since its inception. *Alzheimers Dement.* 2015;11(6):e1–e120.
46. González-Marrero I, Giménez-Llort L, Johanson CE *et al.* Choroid plexus dysfunction impairs beta-amyloid clearance in a triple transgenic mouse model of Alzheimer's disease. *Front. Cell. Neurosci.* 2015; 9: 17.

47. Silverberg GD, Mayo M, Saul T, Rubenstein E, McGuire D. Alzheimer's disease, normal-pressure hydrocephalus, and senescent changes in CSF circulatory physiology: a hypothesis. *Lancet Neurol.* 2003; 2: 506–11.
48. Shuvaev VV, Laffont I, Serot JM, Fujii J, Taniguchi N, Siest G. Increased protein glycation in cerebrospinal fluid of Alzheimer's disease. *Neurobiol. Aging* 2001; 22: 397–402.
49. Kuchler-Bopp S, Dietrich JB, Zaepfel M, Delaunoy JP. Receptor-mediated endocytosis of transthyretin by ependymoma cells. *Brain Res.* 2000; 870: 185–94.
50. Fujiyoshi M, Tachikawa M, Ohtsuki S *et al.* Amyloid- β peptide(1-40) elimination from cerebrospinal fluid involves low-density lipoprotein receptor-related protein 1 at the blood-cerebrospinal fluid barrier. *J. Neurochem.* 2011; 118: 407–15.
51. Pascale CL, Miller MC, Chiu C *et al.* Amyloid-beta transporter expression at the blood-CSF barrier is age dependent. *Fluids Barriers CNS* 2011; 8: 21.
52. Hammad SM, Ranganathan S, Loukinova E, Twal WO, Argraves WS. Interaction of apolipoprotein J-amyloid beta-peptide complex with low density lipoprotein receptor-related protein-2 / megalin. A mechanism to prevent pathological accumulation of amyloid beta-peptide. *J. Biol. Chem.* 1997; 272: 18644–9.
53. Alvira-Botero X, Carro EM. Clearance of amyloid-beta peptide across the choroid plexus in Alzheimer's disease. *Curr. Aging Sci.* 2010; 3: 219–29.
54. Gregory GC, Halliday GM. What is the dominant A β species in human brain tissue? A review. *Neurotox. Res.* 2005; 7: 29–41.
55. Jan A, Hartley DM, Lashuel HA. Preparation and characterization of toxic A β aggregates for structural and functional studies in Alzheimer's disease research. *Nat. Protoc.* 2010; 5: 1186–209.
56. Monro OR, Mackic JB, Yamada S *et al.* Substitution at codon 22 reduces clearance of Alzheimer's amyloid-beta peptide from the cerebrospinal fluid and prevents its transport from the central nervous system into blood. *Neurobiol. Aging* 2002; 23: 405–12.

57. Banks WA, Kastin AJ, Michals EA. Transport of thyroxine across the blood-brain barrier is directed primarily from brain to blood in the mouse. *Life. Sci.* 1985; 37: 2407–14.

FIGURE 1 $^{125}\text{I-T}_4$ efflux after lateral ventricle injection. Levels of $^{125}\text{I-T}_4$ and its size matched extracellular marker $^3\text{H-mannitol}$ fell over time in whole brain. (a) $^{125}\text{I-T}_4$ was cleared faster than $^3\text{H-mannitol}$ at the baseline. The addition of TTR (b) 50 $\mu\text{g/mL}$; (c) 200 $\mu\text{g/mL}$) slowed the $^{125}\text{I-T}_4$ clearance but did not affected ^3H mannitol one. Solid squares are $^{125}\text{I-T}_4$ LogVd while open squares represent $^3\text{H-mannitol}$ LogVd. Values are mean \pm SEM, n = 3–5.

FIGURE 2 $^{125}\text{I-A}\beta 40$ efflux after lateral ventricle injection. Levels of $^{125}\text{I-A}\beta 40$ and its size matched extracellular marker $^3\text{H-inulin}$ fell over time in whole brain. (a) $^{125}\text{I-A}\beta 40$ was cleared faster than $^3\text{H-inulin}$ at the baseline. The addition of TTR (b) 50 $\mu\text{g/mL}$; (c) 200 $\mu\text{g/mL}$) did not affect the $^{125}\text{I-A}\beta 40$ and $^3\text{H-inulin}$ clearance (b, c). Solid circles are $^{125}\text{I-A}\beta 40$ LogVd, while open circles represent $^3\text{H-inulin}$ LogVd. Values are mean \pm SEM, n=3–5.

FIGURE 3 Regional brain uptake of $^{125}\text{I-T}_4$ at 16 minutes post lateral ventricle injection. Baseline uptake of $^{125}\text{I-T}_4$ showed highest accumulation in the CP (choroid plexus). The ependymal ventricular lining (EP) also showed some uptake of $^{125}\text{I-T}_4$, however, the rest of the brain did not show much uptake. The addition of TTR to the lateral ventricles resulted in increased retention of $^{125}\text{I-T}_4$ in the CP, and the increase reached significance with TTR 200 $\mu\text{g/mL}$. The addition of TTR did not change retention of $^{125}\text{I-T}_4$ in EP, HC, FX and CB. HC, hippocampus; FX, front cortex; CB, cerebellum. Values are mean \pm SEM, n=3–5. *means $P < 0.05$ compared to baseline.

FIGURE 4 Regional brain uptake of $^{125}\text{I-A}\beta 40$ at 16 minutes post lateral ventricle injection. Baseline uptake of $^{125}\text{I-A}\beta 40$ showed highest accumulation in the CP (choroid plexus). Brain parenchymal uptake was lower, and only the ependymal ventricular lining (EP) showed some uptake of $^{125}\text{I-A}\beta 40$. The addition of TTR to the lateral ventricles resulted in significant increased retention of $^{125}\text{I-A}\beta 40$ in the CP, but did not change retention of $^{125}\text{I-A}\beta 40$ in EP, HC, FX and CB. HC, hippocampus; FX, front cortex; CB, cerebellum. Values are mean \pm SEM, n = 3–5. * means $P < 0.05$ compared to baseline.